Moderna (NASDAQ:MRNA) Shares Gap Down - Here's What Happened

Key Points

• Moderna and Merck's personalized cancer vaccine (intismeran plus Keytruda) showed roughly a 49% reduction in risk of recurrence or death at five years in high‑risk melanoma, sparking a rally and pushing shares to a 52‑week high as investors price in an oncology pivot.
• Despite the rally, shares gapped down premarket (closed $51.87, opened $49.81) and last traded near $47.53 on heavy volume, with momentum and profit‑taking cited as risks for a short‑term pullback.
• Longer‑term caution remains: the CEO said Moderna will curb investments in new late‑stage vaccine trials amid U.S. backlash, while analysts' consensus rating is "Reduce" with an average price target of $30.36.

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $51.87, but opened at $49.81. Moderna shares last traded at $47.5320, with a volume of 4,393,569 shares.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Five‑year Phase IIb results: Moderna and Merck reported the personalized cancer vaccine (intismeran autogene plus Keytruda) cut the risk of recurrence or death by ~49% in high‑risk melanoma — a major clinical win that drove the rally. MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data
• Positive Sentiment: Market reaction and sentiment: Coverage from major outlets notes shares surged, extended a year‑to‑date rally and reached a 52‑week high as investors price in the potential of a cancer vaccine and a broader oncology pipeline to replace weaker respiratory vaccine revenues. Moderna Stock Is Surging. Why a Cancer Vaccine Study Has Sparked a Rally.
• Neutral Sentiment: Wider market and visibility: Moderna is a trending ticker across market roundups and tech/health coverage, which amplifies intraday moves but doesn’t change fundamentals by itself. Trending tickers: AMD, Intel, Moderna...
• Negative Sentiment: CEO says Moderna will curb investments in new late‑stage vaccine trials due to U.S. political/backlash concerns — a signal that the company may reallocate R&D capital away from some vaccine programs, which could limit near‑term revenue opportunities outside the oncology wins. Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV
• Negative Sentiment: Momentum and profit‑taking risk: Several pieces note sharp short‑term gains and momentum indicators that suggest caution — typical catalysts for a pullback as traders lock in profits after a rapid move. Moderna shares soar through the week, momentum data points toward caution

Analyst Ratings Changes

MRNA has been the subject of several research analyst reports. Berenberg Bank set a $28.00 price objective on shares of Moderna in a research report on Monday, November 17th. Needham & Company LLC restated a "hold" rating on shares of Moderna in a research note on Monday, October 20th. Royal Bank Of Canada reiterated a "sector perform" rating on shares of Moderna in a research note on Monday, January 12th. Citigroup reissued a "neutral" rating on shares of Moderna in a report on Monday. Finally, Wolfe Research restated an "underperform" rating and issued a $17.00 target price on shares of Moderna in a research note on Thursday, November 20th. Two investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Reduce" and an average price target of $30.36.

Moderna Price Performance

The firm's fifty day simple moving average is $31.29 and its 200 day simple moving average is $28.68. The company has a market capitalization of $18.86 billion, a PE ratio of -5.97 and a beta of 1.17.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $893.29 million. During the same quarter last year, the business posted $0.03 EPS. The company's revenue was down 45.4% on a year-over-year basis. On average, equities research analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Insider Transactions at Moderna

In other Moderna news, Director Noubar Afeyan sold 23,853 shares of the company's stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total value of $703,186.44. Following the sale, the director owned 3,924 shares in the company, valued at approximately $115,679.52. This represents a 85.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 10.90% of the company's stock.

Hedge Funds Weigh In On Moderna

Several large investors have recently made changes to their positions in the company. Norges Bank purchased a new position in shares of Moderna in the 2nd quarter valued at about $94,910,000. Vanguard Group Inc. boosted its position in Moderna by 3.2% during the second quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company's stock worth $1,150,743,000 after purchasing an additional 1,312,192 shares in the last quarter. Legal Advantage Investments Inc. acquired a new stake in Moderna in the third quarter valued at approximately $1,244,000. Letko Brosseau & Associates Inc. increased its position in shares of Moderna by 2.4% in the second quarter. Letko Brosseau & Associates Inc. now owns 918,190 shares of the company's stock valued at $25,333,000 after buying an additional 21,765 shares in the last quarter. Finally, Thrivent Financial for Lutherans increased its position in shares of Moderna by 600.7% in the second quarter. Thrivent Financial for Lutherans now owns 92,999 shares of the company's stock valued at $2,566,000 after buying an additional 79,726 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.